Syndax Pharmaceuticals (SNDX) Stock Statistics & Valuation Metrics

Syndax Pharmaceuticals has a market cap or net worth of $2.07B. The enterprise value is $2.33B.

Syndax Pharmaceuticals has 88,200,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Syndax Pharmaceuticals’s return on equity (ROE) is -4.42 and return on invested capital (ROIC) is -66.60%.

The current PE Ratio of Syndax Pharmaceuticals is ―. Syndax Pharmaceuticals’s PEG ratio is 0.55.

In the last 12 months, Syndax Pharmaceuticals had revenue of 172.35M and earned -285.42M in profits. Earnings per share was -3.30.

In the last 12 months, operating cash flow was -322.98M and capital expenditures -187.00K, giving a free cash flow of -323.17M billion.

Syndax Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Syndax Pharmaceuticals upcoming earnings date is May 11, 2026, After Close (Confirmed).

Syndax Pharmaceuticals as a current ratio of 4.40, with Debt / Equity ratio of 536.10%

In the past 12 months, Syndax Pharmaceuticals has paid 0.00 in taxes.

Syndax Pharmaceuticals EV to EBITDA ratio is -8.07, with an EV/FCF ratio of -6.29.

Syndax Pharmaceuticals has $394.07M in cash and marketable securities with $346.48M in debt, giving a net cash position of $47.59M billion.

Gross margin is 95.96%, with operating margin of -158.45%, and net profit margin of -165.60%.

The average price target for Syndax Pharmaceuticals is $42.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy